Cargando…
Correction to: Nadofaragene Firadenovec: First Approval
Autor principal: | Lee, Arnold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285007/ https://www.ncbi.nlm.nih.gov/pubmed/37269456 http://dx.doi.org/10.1007/s40265-023-01902-8 |
Ejemplares similares
-
Nadofaragene Firadenovec: First Approval
por: Lee, Arnold
Publicado: (2023) -
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval
por: Martini, Alberto, et al.
Publicado: (2023) -
Correction to: Fuzuloparib: First Approval
por: Lee, Arnold
Publicado: (2021) -
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021) -
Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)